A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer

A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer

Objective: Intravesical bacillus Calmette-Guerin (BCG) therapy is considered to be the most effective therapy for high-risk superficial cancer of bladder. Reduction in dose has been tried to decrease the toxicity following instillations of BCG while maintaining efficacy. This study compares the ef...

Full description

Bibliographic Details
Main Authors: Vivek Vijjan, Anil Mandhani, Rakesh Kapoor, Deepak Dubey, Aneesh Srivastava, M S Ansari, Pratipal Singh, Anant Kumar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2006-01-01
Series:Indian Journal of Urology
Subjects:
Bacillus Calmette-Guerin low dose
superficial bladder cancer
Online Access:http://www.indianjurol.com/article.asp?issn=0970-1591;year=2006;volume=22;issue=4;spage=317;epage=321;aulast=Vijjan

Internet

http://www.indianjurol.com/article.asp?issn=0970-1591;year=2006;volume=22;issue=4;spage=317;epage=321;aulast=Vijjan

Similar Items